Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.
Event: Jefferies Virtual Global Healthcare Conference Place: Waldorf Hilton, London Presentation Date: November 17-19, 2020 Format: One-on-one sessions
The presentation will be accessible on the events page under the investor relations section of Tyme Technologies’ website at www.tymeinc.com.
SM-88 is an oral investigational modified proprietary tyrosine derivative that